Mycobacterium intracellulare Pulmonary Disease with Endobronchial Caseation in a Patient Treated with Methotrexate.
- Author:
Jin Sun PARK
1
;
Eul Sik JUNG
;
Woosuk CHOI
;
Soo Yong PARK
;
Min Young RIM
;
Inku YU
;
Hyeonsu PARK
;
Sang Min LEE
;
Jeong Woong PARK
;
Sung Hwan JEONG
;
Sang Pyo LEE
;
Sanghui PARK
Author Information
- Publication Type:Case Report
- Keywords: Nontuberculous Mycobacteria; Tuberculosis, Pulmonary; Methotrexate; Arthiritis, Rheumatoid; Bronchial Diseases
- MeSH: Arthritis, Rheumatoid; Bronchial Diseases; Female; Humans; Lung Diseases; Methotrexate; Mycobacterium; Mycobacterium avium Complex; Nontuberculous Mycobacteria; Opportunistic Infections; Tuberculosis, Pulmonary
- From:Tuberculosis and Respiratory Diseases 2013;75(1):28-31
- CountryRepublic of Korea
- Language:English
- Abstract: Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.
